RECRUITINGOBSERVATIONAL
Prognosis of Early-onset Anorexia Nervosa
Evalutation of the Prognosis and Quality of Life of Patients Hospitalized for Early-onset Anorexia Nervosa
About This Trial
The AM2P study aims to evaluate the long-term prognosis and quality of life of patients with early-onset anorexia nervosa, assessed 4 to 9 years after hospitalization. Prognosis will be determined using a composite outcome measure based on questionnaire responses and health indicators, including body mass index (BMI). In addition, the study will examine the patients' overall physical condition both at the time of assessment and during the interval between their last hospitalization and the present evaluation.
Who May Be Eligible (Plain English)
Who May Qualify:
- First full hospitalization in the eating disorders unit (EDU) at Robert Debré Hospital and diagnosis of AMP from 2016 to 2021
- No objection from the minor to the study
- Proficiency and understanding of the French language
- Access to digital technology (computer, smartphone, tablet, etc.)
Who Should NOT Join This Trial:
- Primary diagnosis of ARFID, other unspecified eating disorder
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* First full hospitalization in the eating disorders unit (EDU) at Robert Debré Hospital and diagnosis of AMP from 2016 to 2021
* No objection from the minor to the study
* Proficiency and understanding of the French language
* Access to digital technology (computer, smartphone, tablet, etc.)
Exclusion Criteria:
* Primary diagnosis of ARFID, other unspecified eating disorder
Locations (1)
Hopital Robert Debre - AP-HP
Paris, France